AK104 for Recurrent or Metastatic Vulvar Cancer
A phase 2 trial of Cadonilimab, Paclitaxel / nab-paclitaxel in vulvar cancer, run by Akeso, now recruiting.
Overview
AK104 for Recurrent or Metastatic Vulvar Cancer is a phase 2 interventional study registered as NCT05932212 by Akeso, with 20 participants planned, started 2023-08-25 and due to reach its primary completion in 2025-12-15. Interventions recorded: AK104, AK104+ Paclitaxel+Cisplatin or Carboplatin. Conditions listed: Vulvar Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Shares Cadonilimab, Akeso.
- TrialA Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Shares Cadonilimab, Akeso.
- TrialAK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Shares Cadonilimab, Akeso, Paclitaxel / nab-paclitaxel.
- TrialA Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
Shares Cadonilimab, Akeso.
- TrialAn Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
Shares Cadonilimab, Akeso.
- TrialA Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat
Shares Cadonilimab, Akeso.
- TrialAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Shares Cadonilimab, Akeso, Paclitaxel / nab-paclitaxel.
- TrialCOMPASSION-16 / AK104-303
Shares Cadonilimab, Akeso, Paclitaxel / nab-paclitaxel.